The put/call ratio of MCRB is 0.39, indicating a bullish outlook. Analyst Price Forecast Suggests 72.62% Upside. As of April 24, 2023, the average one-year price target for Seres Therapeutics is ...markets.businessinsider.com - May 9 at 5:40 PM. Oppenheimer Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $4.00. marketbeat.com - May 9 at 1:55 PM. Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023) finance.yahoo.com - May 9 at 12:07 PM.1 Watchlist. Introducing Litepaper, a newsletter by Stocktwits. Your lens into the world of crypto. See all Stocktwits emails. The latest messages and market ideas from David Levin (@mcrb) on Stocktwits. The largest community for investors and traders.

6 days ago · See the latest Seres Therapeutics Inc stock price (MCRB:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The put/call ratio of MCRB is 0.39, indicating a bullish outlook. Analyst Price Forecast Suggests 72.62% Upside. As of April 24, 2023, the average one-year price target for Seres Therapeutics is ...MCRB stock closed at $5.33 and is down -$0.05 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. MCRB has a strong overall score of 72 meaning the stock holds a better value than 72% of stocks at its current price.

erika castillo husband See why we rate MCRB stock a hold currently. SER-109 (Vowst) was recently approved by FDA and will be launched in June with the Nestle commercial team. See why we rate MCRB stock a hold currently. alabama buc ee's locationsanderson county dump hours For the last reported quarter, it was expected that Seres Therapeutics would post a loss of $0.41 per share when it actually produced a loss of $0.54, delivering a surprise of -31.71%. The company ...Get the latest Seres Therapeutics, Inc. (MCRB) stock news and headlines to help you in your trading and investing decisions. wingstop 7th street Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company ... Recently, investors have seen the share price of Seres Therapeutics (NASDAQ:MCRB) fall after an FDA approval. While I rated Seres a buy in an article in 2020 before the phase 3 SER-109 readout, my ... i80 road conditions in wyomingtides4fishhyundai oil consumption fix Seres Therapeutics ( MCRB) will sell 10.5 million shares at $21.50 per share, the company said late Wednesday. It also will sell 959,002 shares to Swiss food giant Nestle. That company, through ... franklin regional jail Find the latest Seres Therapeutics, Inc. (MCRB) stock quote, history, news and other vital information to help you with your stock trading and investing. Seres Therapeutics (MCRB) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open.The consensus EPS Estimate is -$0.54 and the consensus Revenue Estimate... cal poly san luis obispo transfer acceptance ratechili's grill and bar houma menujet's pizza promo code MCRB Stock Chart & Stats. Advanced Chart >. -40.65%. Day’s Range $0 - $0. 52-Week Range $0.71 - $6.87. Previous Close $0.73. Volume 2.89M. Average Volume (3M) 4.06M. Market Cap.